Questions About Cancer? 1-800-4-CANCER

Late Effects of Treatment for Childhood Cancer (PDQ®)

Health Professional Version

Late Effects of the Endocrine System

Thyroid Gland

Thyroid dysfunction is a common delayed effect of radiation therapy fields that include the thyroid gland incidental to treating Hodgkin lymphoma (HL), brain tumors, head and neck sarcomas, and acute lymphoblastic leukemia. It is manifested by the following:

  • Primary hypothyroidism.
  • Hyperthyroidism.
  • Goiter.
  • Nodules.


Of children treated with radiation therapy, most develop hypothyroidism within the first 2 to 5 years posttreatment, but new cases can occur later. Reports of thyroid dysfunction differ depending on the dose of radiation, the length of follow-up, and the biochemical criteria utilized to make the diagnosis.[1] The most frequently reported abnormalities include:

  • Elevated thyroid-stimulating hormone (TSH).
  • Depressed thyroxine (T4).
  • Elevated TSH and depressed T4.

Compensated hypothyroidism includes an elevated TSH with a normal T4 and is asymptomatic. The natural history is unclear, but most endocrinologists support treatment. Uncompensated hypothyroidism includes both an elevated TSH and a depressed T4. Thyroid hormone replacement is beneficial for correction of the metabolic abnormality, and has clinical benefits for cardiovascular, gastrointestinal, and neurocognitive function.

An increased risk of hypothyroidism has been reported among childhood cancer survivors treated with head and neck radiation exposing the thyroid gland, especially among survivors of Hodgkin lymphoma. Results from selected studies include the following:

  • In a study of 1,713 adult survivors of childhood cancers and brain tumors (median age, 32 years) monitored in a single institution (median follow-up duration, 25 years), the prevalence of primary hypothyroidism among individuals exposed to neck radiation was 13.8%.[2]
  • The German Group of Paediatric Radiation Oncology reported on 1,086 patients treated at 62 centers, including 404 patients (median age, 10.9 years) who received radiation therapy to the thyroid gland and/or hypophysis.[3] Follow-up information was available for 264 patients (60.9%; median follow-up, 40 months), with 60 patients (22.7%) showing pathologic values. The following was observed:
    • In comparison to patients treated with prophylactic cranial radiation (median dose, 12 Gy), patients treated with radiation doses of 15 Gy to 25 Gy to the thyroid gland had a hazard ratio (HR) of 3.072 (P = .002) for the development of pathologic thyroid blood values.
    • Patients treated with more than 25 Gy of radiation to the thyroid gland had an HR of 3.769 (P = .009), and patients treated with craniospinal radiation had an HR of 5.674 (P < .001).
    • The cumulative incidence of thyroid hormone substitution therapy did not differ between defined subgroups.
  • In a cohort of childhood HL survivors treated between 1970 and 1986, survivors were evaluated for thyroid disease by use of a self-report questionnaire in the Childhood Cancer Survivor Study (CCSS).[4] Among 1,791 survivors, 34% reported that they had been diagnosed with at least one thyroid abnormality. For hypothyroidism, there was a clear dose response, with a 20-year risk of:
    • 20% for those who received less than 35 Gy of radiation to the thyroid gland.
    • 30% for those who received 35 Gy to 44.9 Gy of radiation to the thyroid gland.
    • 50% for those who received more than 45 Gy of radiation to the thyroid gland.

    The relative risk (RR) was 17.1 for hypothyroidism; 8.0 for hyperthyroidism; and 27.0 for thyroid nodules. Elapsed time since diagnosis was a risk factor for both hypothyroidism and hyperthyroidism, with the risk increasing in the first 3 to 5 years postdiagnosis. For nodules, the risk increased beginning at 10 years postdiagnosis. Females were at increased risk for hypothyroidism and thyroid nodules.

    Probability of developing hypothyroidism according to radiation dose in 5-year survivors of childhood cancer; graph shows the proportion not affected in years since diagnosis for no RT, less than 3500 cGy, 3500-4499 cGy, and ≥4500 cGy.
    Figure 4. Probability of developing hypothyroidism according to radiation dose in 5-year survivors of childhood cancer. Data from the Childhood Cancer Survivor Study.[4] Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, Greffe B, Wolden S, Robison L: Abnormalities of the Thyroid in Survivors of Hodgkin's Disease: Data from the Childhood Cancer Survivor Study. The Journal of Clinical Endocrinology and Metabolism 85 (9): 3227-3232, September 1, 2000. Copyright 2000, The Endocrine Society.

Thyroid nodules

Any radiation field that includes the thyroid is associated with an excess risk of thyroid neoplasms, which may be benign (usually adenomas) or malignant (most often differentiated papillary carcinoma).[4-8] The clinical manifestation of thyroid neoplasia among childhood cancer survivors ranges from asymptomatic, small, solitary nodules to large, intrathoracic goiters that compress adjacent structures. CCSS investigators performed a nested case-control study to evaluate the magnitude of risk for thyroid cancer over the therapeutic radiation dose range of pediatric cancers. The risk of thyroid cancer increased with radiation doses up to 20 Gy to 29 Gy (odds ratio [OR], 9.8; 95% confidence interval [CI], 3.2–34.8), but declined at doses higher than 30 Gy, consistent with a cell-killing effect.[8]

The following factors are linked to an increased risk of thyroid nodule development:

  • Time from diagnosis, female gender, and radiation dose. In a study of HL survivors, CCSS investigators identified time from diagnosis, female gender, and radiation dose of 25 Gy or more as significant risk factors for thyroid nodule development.[4] Based on a cohort of 3,254 2-year childhood cancer survivors treated before 1986 and monitored for 25 years, the risk of thyroid adenoma increased with the size of the radiation dose to the thyroid during childhood cancer treatment and plateaued at doses exceeding 10 Gy.[6]
  • Age at time of radiation therapy. Based on the same cohort of 3,254 2-year childhood cancer survivors, the risk of thyroid adenoma per unit of radiation dose to the thyroid was higher if radiation therapy had been delivered before age 5 years; the risk was also higher in individuals who were younger than 40 years at the time of the study.[6] Younger age at radiation therapy has also been linked to an excess risk of thyroid carcinoma.[5-8]
  • Exposure to iodine I 131 metaiodobenzylguanidine (131I-mIBG). During childhood and adolescence, there is an increased incidence of developing thyroid nodules, and potentially thyroid cancer, for patients exposed to 131I-mIBG. Children who have been treated with 131I-mIBG should undergo lifelong monitoring, not only for thyroid function but also for the development of thyroid nodules and thyroid cancer.[9]
  • Chemotherapy. Whereas the risk of thyroid cancer is known to be increased by exposure to radiation therapy and 131I-mIBG, an increased risk of thyroid nodules and cancer has also been observed in association with chemotherapy, independent of radiation exposure.[5,6]

    In a pooled study of two cohorts of 16,757 survivors that included 187 patients with secondary thyroid cancer, treatments with alkylating agents, anthracyclines, or bleomycin were associated with a significantly increased risk of thyroid cancer in individuals not exposed to radiation therapy.[10] Defining the precise role of exposure to chemotherapy and developing risk prediction models for thyroid cancer in childhood cancer survivors based on demographic and treatment-related risk factors are areas of active research.[11]

Several investigations have demonstrated the superiority of ultrasound to clinical exam for detecting thyroid nodules and thyroid cancers and characterized ultrasonographic features of nodules that are more likely to be malignant.[12,13] However, primary screening for thyroid neoplasia (beyond physical exam with thyroid palpation) remains controversial because of the lack of data indicating a survival benefit and quality-of-life benefit associated with early detection and intervention. In fact, because these lesions tend to be indolent, are rarely life-threatening, and may clinically manifest many years after exposure to radiation, there are significant concerns regarding the costs and harms of overscreening.[14]

(Refer to the Subsequent Neoplasms section of this summary for information about subsequent thyroid cancers.)

Posttransplant thyroid dysfunction

Survivors of pediatric hematopoietic stem cell transplantation (HSCT) are at increased risk of thyroid dysfunction, with the risk being much lower (15%–16%) after fractionated total-body irradiation (TBI), as opposed to single-dose TBI (46%–48%). Non–TBI-containing regimens historically were not associated with an increased risk. However, in a report from the Fred Hutchinson Cancer Research Center, the increased risk of thyroid dysfunction did not differ between children receiving a TBI-based or busulfan-based regimen (P = .48).[15] Other high-dose therapies have not been studied.

Table 7. Thyroid Late Effects
Predisposing TherapyEndocrine/Metabolic EffectsHealth Screening
mIBG = metaiodobenzylguanidine; T4 = thyroxine; TSH = thyroid-stimulating hormone.
Radiation impacting thyroid gland; thyroidectomyPrimary hypothyroidismTSH level
Radiation impacting thyroid glandHyperthyroidismFree T4 level
TSH level
Radiation impacting thyroid gland, including mIBGThyroid nodulesThyroid exam
Thyroid ultrasound

TSH deficiency (central hypothyroidism) is discussed with late effects that affect the pituitary gland.

Pituitary Gland

Survivors of childhood cancer are at risk for a spectrum of neuroendocrine abnormalities, primarily because of the effect of radiation therapy on the hypothalamus. In addition, tumor development or surgical resection close to the hypothalamus and/or pituitary gland may induce direct anatomical damage to these structures and result in hypothalamic/pituitary dysfunction. Essentially all of the hypothalamic-pituitary axes are at risk.[2,16-18]

Central diabetes insipidus

Central diabetes insipidus may herald the diagnosis of craniopharyngioma, suprasellar germ cell tumor, or Langerhans cell histiocytosis.[19-21] In these conditions, diabetes insipidus may occur as an isolated pituitary deficiency, although additional pituitary hormone deficiencies may develop with tumor progression. More commonly, however, diabetes insipidus occurs in the context of panhypopituitarism caused by the presence of a tumor in close proximity to the sellar region or as a consequence of surgical procedures undertaken for local tumor control.

Central diabetes insipidus has not been reported as a late effect of cranial radiation in childhood cancer survivors.

Anterior pituitary hormone deficiency

Deficiencies of anterior pituitary hormones and major hypothalamic regulatory factors are common late effects among survivors treated with cranial irradiation. In a study of 1,713 adult survivors of childhood cancers and brain tumors (median age, 32 years) monitored in a single institution (median follow-up duration, 25 years), the prevalence of hypothalamic-pituitary axis disorders was 56.4% in individuals exposed to cranial radiation therapy at doses of 18 Gy or more.[2] The six anterior pituitary hormones and their major hypothalamic regulatory factors are outlined in Table 8.

Table 8. Anterior Pituitary Hormones and Major Hypothalamic Regulatory Factors
Pituitary HormoneHypothalamic FactorHypothalamic Regulation of the Pituitary Hormone
(–) = inhibitory; (+) = stimulatory.
Growth hormone (GH)Growth hormone–releasing hormone+
Luteinizing hormone (LH)Gonadotropin-releasing hormone+
Follicle-stimulating hormone (FSH)Gonadotropin-releasing hormone+
Thyroid-stimulating hormone (TSH)Thyroid-releasing hormone+
Adrenocorticotropin (ACTH)Corticotropin-releasing hormone+

Growth hormone deficiency

Growth hormone deficiency (GHD) is the earliest hormonal deficiency associated with cranial radiation in childhood cancer survivors. The risk increases with radiation dose and time since treatment. GHD is sensitive to low doses of radiation. Other hormone deficiencies require higher doses, and their time to onset is much longer than for GHD.[22] The prevalence in pooled analysis was found to be approximately 35.6%.[23]

GHD is commonly observed in these long-term survivors because of radiation doses used in the treatment of childhood brain tumors. Approximately 60% to 80% of irradiated pediatric brain tumor patients who received doses higher than 30 Gy will have impaired serum growth hormone (GH) response to provocative stimulation, usually within 5 years of treatment. The dose-response relationship has a threshold of 18 Gy to 20 Gy; the higher the radiation dose, the earlier that GHD will occur after treatment.

  • A study of conformal radiation therapy (CRT) in children with central nervous system (CNS) tumors indicates that GH insufficiency can usually be demonstrated within 12 months of radiation therapy, depending on hypothalamic dose-volume effects.[24]
  • In a report featuring data from 118 patients with localized brain tumors who were treated with radiation therapy, peak GH was modeled as an exponential function of time after CRT and mean radiation dose to the hypothalamus. The average patient was predicted to develop GHD with the following combinations of time after CRT and mean dose to the hypothalamus: 12 months and more than 60 Gy; 36 months and 25 Gy to 30 Gy; and 60 months and 15 Gy to 20 Gy. A cumulative dose of 16.1 Gy to the hypothalamus would be considered the mean radiation dose required to achieve a 50% risk of GHD at 5 years (TD50/5).[25]

Graph shows peak growth hormone (in ng/mL) according to hypothalamic mean dose and time (in months) after start of irradiation.
Figure 5. Peak growth hormone (GH) according to hypothalamic mean dose and time after start of radiation. According to equation 2, peak GH = exp{2.5947 + time × [0.0019 − (0.00079 × mean dose)]}.[25] Thomas E. Merchant, Susan R. Rose, Christina Bosley, Shengjie Wu, Xiaoping Xiong, and Robert H. Lustig, Growth Hormone Secretion After Conformal Radiation Therapy in Pediatric Patients With Localized Brain Tumors, Journal of Clinical Oncology, volume 29, issue 36, pages 4776-4780. Reprinted with permission. © (2011) American Society of Clinical Oncology. All rights reserved.

Children treated with CNS-directed therapy for leukemia are also at increased risk of GHD. Results from selected studies of childhood acute lymphocytic leukemia (ALL) survivors are as follows:

  • One study evaluated 127 patients with ALL treated with 24 Gy, 18 Gy, or no cranial radiation. The change in height, compared with population norms expressed as the standard deviation score (SDS), was significant for all three groups, with a dose response of -0.49 ± 0.14 for the group that did not receive radiation therapy, -0.65 ± 0.15 for the group that received 18 Gy of radiation therapy , and -1.38 ± 0.16 for the group that received 24 Gy of radiation therapy.[26]
  • Another study found similar results in 118 ALL survivors treated with 24 Gy cranial radiation, in which 74% had SDS of -1 or higher and the remainder had scores of -2 or higher.[27]
  • Survivors of childhood ALL who are treated with chemotherapy alone are also at increased risk for adult short stature, although the risk is highest for those treated with cranial and craniospinal radiation therapy at a young age.[28] In this cross-sectional study, attained adult height was determined among 2,434 ALL survivors participating in the CCSS.
    • All survivor treatment exposure groups (chemotherapy alone and chemotherapy with cranial or craniospinal radiation therapy) had decreased adult height and an increased risk of adult short stature (height SDS < -2), compared with siblings (P < .001).
    • Compared with siblings, the risk of short stature for survivors treated with chemotherapy alone was elevated (OR, 3.4; 95% CI, 1.9–6.0).
    • Among survivors, significant risk factors for short stature included diagnosis of ALL before puberty, higher-dose cranial radiation therapy (≥20 Gy vs. <20 Gy), any radiation therapy to the spine, and female gender.
  • The impact of chemotherapy alone on growth in 67 survivors treated with contemporary regimens for ALL was statistically significant at -0.59 SD. The loss of growth potential did not correlate with GH status in this study, further highlighting the participation of other factors in the growth impairments observed in this population.[29]

Children who undergo HSCT with TBI have a significant risk of both GHD and the direct effects of radiation on skeletal development. The risk is increased with single-dose TBI as opposed to fractionated TBI, pretransplant cranial radiation, female gender, and posttreatment complications such as graft-versus-host disease (GVHD).[30-32] Regimens containing busulfan and cyclophosphamide appear to increase risk in some studies,[32,33] but not others.[34] Hyperfractionation of the TBI dose markedly reduces risk in patients who have not undergone pretransplant cranial radiation for CNS leukemia prophylaxis or therapy.[35]

The late effects that occur after HSCT have been studied and reviewed by the Late Effect Working Party of the European Group for Blood and Marrow Transplantation. Among 181 patients with aplastic anemia, leukemias, and lymphomas who underwent HSCT before puberty, the following results were observed:[36,37]

  • An overall decrease in final height-SDS value was found, compared with height at transplant and genetic height. The mean loss of height is estimated to be approximately 1 height-SDS (6 cm), compared with the mean height at time of HSCT and mean genetic height.
  • The type of transplantation, GVHD, and GH or steroid treatment did not influence final height.
  • TBI (single-dose radiation therapy more than fractionated-dose radiation therapy), male gender, and young age at transplant were found to be major factors for long-term height loss. Most patients (140 of 181) reached adult height within the normal range of the general population.

GHD replacement therapy provides the benefit of optimizing height outcomes among children who have not reached skeletal maturity. Treatment with recombinant GH (rGH) replacement therapy is generally delayed until 12 months after successful completion of cancer or brain tumor treatments and after a multidisciplinary discussion involving the prescribing pediatric endocrinologist, the primary oncologist, and other providers selected by the patient or family. Safety concerns pertaining to the use of rGH in childhood cancer survivors have primarily been related to the mitogenic potential of the GH stimulating tumor growth in a population with an increased risk of second neoplasms.[38] Most studies that report these outcomes, however, are limited by selection bias and small sample size.

The following study results have been reported in survivors who did or did not receive treatment with GH:

  • One study evaluated 361 GH-treated cancer survivors enrolled in the CCSS and compared risk of recurrence, risk of subsequent neoplasm, and risk of death among survivors who did and did not receive treatment with GH.[39]
    • The RR of disease recurrence was 0.83 (95% CI, 0.37–1.86) for GH-treated survivors. GH-treated subjects were diagnosed with 15 subsequent neoplasms, all solid tumors, for an overall RR of 3.21 (95% CI, 1.88–5.46), mainly because of a small excess number of subsequent neoplasms observed in survivors of acute leukemia.[39] With prolonged follow-up, the elevation of subsequent cancer risk due to GH diminished.[40]
    • Compared with survivors not treated with GH, those who were treated had a twofold excess risk of developing a subsequent neoplasm (RR, 2.15; 95% CI, 1.33–3.47; P < .002); meningiomas were the most commonly observed (9 of 20 tumors).
  • A review of existing data suggests that treatment with GH is not associated with an increased risk of CNS tumor progression or recurrence, or new or recurrent leukemia.[41]
  • A recent study from the CCSS reported specifically on the risk of subsequent CNS neoplasms after a longer period of follow-up. The adjusted rate ratio of meningioma and gliomas in GH-treated survivors of CNS tumors was 1.0 (95% CI, 0.6–1.8; P = .94) when compared with CNS tumor survivors who were not treated with GH, thus indicating negligible differences between the two groups for this particular risk.[42]

In general, the data addressing subsequent malignancies should be interpreted with caution given the small number of events.[38,39]

Disorders of luteinizing hormone (LH) and follicle-stimulating hormone (FSH): Central precocious puberty and LH/FSH deficiency

Pubertal development can be adversely affected by cranial radiation. Doses higher than 18 Gy can result in central precocious puberty, while doses higher than 30 Gy to 40 Gy may result in LH and FSH deficiency.[43]

Central precocious puberty

Central precocious puberty is defined by the onset of pubertal development before age 8 years in girls and 9 years in boys as a result of the premature activation of the hypothalamic-pituitary-gonadal axis. Aside from the adjustment and psychosocial challenges associated with early pubertal development, precocious puberty can lead to the rapid closure of the skeletal growth plates and short stature. This deleterious effect can be further potentiated by GHD.[44] The increased growth velocity induced by pubertal development can mask concurrent GHD with seemingly normal growth velocity; this occurrence may mislead care providers. It is also important to note that the assessment of puberty cannot be performed using testicular volume measurements in boys exposed to chemotherapy or direct radiation to the testes, given the toxic effect of these treatments on germ cells and repercussions on gonadal size. The staging of puberty in males within this population relies on the presence of other signs of virilization, such as the presence of pubic hair and the measurement of plasma testosterone levels.[44]

Central precocious puberty has been reported in some children receiving cranial radiation in doses of 24 Gy or higher. Earlier puberty and earlier peak height velocity, however, have been observed in girls treated with 18 Gy cranial radiation.[45,46] The impact of central precocious puberty on linear growth can be ascertained by assessing the degree of skeletal maturation (or bone age) using an x-ray of the left hand.[47]

When appropriate, delaying the progression of puberty relies on the use of various gonadotropin-releasing hormone agonist preparations, an approach that has been shown to improve growth prospects—especially when other pituitary abnormalities, including GHD, are concurrently treated.[48]

LH/FSH deficiency

LH/FSH deficiency (also referred to as hypogonadotropic hypogonadism) can manifest through pubertal delay, arrested puberty, or symptoms of decreased sex hormone production, depending on age and pubertal status at the time of diagnosis. With higher doses of cranial radiation (>35 Gy), deficiencies in LH/FSH can be seen, with a cumulative incidence of 10% to 20% at 5 to 10 years posttreatment.[49,50] The treatment of LH/FSH deficiency relies on sex-hormone replacement therapy adjusted to age and pubertal status.

TSH deficiency

TSH deficiency (also referred to as central hypothyroidism) in survivors of childhood cancer can have profound clinical consequences and be underappreciated. Symptoms of central hypothyroidism (e.g., asthenia, edema, drowsiness, and skin dryness) may have a gradual onset and go unrecognized until thyroid replacement therapy is initiated. In addition to delayed puberty and slow growth, hypothyroidism may cause fatigue, dry skin, constipation, increased sleep requirement, and cold intolerance. Individuals with TSH deficiency have low plasma free T4 levels and either low or inappropriately normal TSH levels.

Radiation dose to the hypothalamus in excess of 42 Gy is associated with an increased risk of developing TSH deficiency (44% ± 19% for dose of ≥42 Gy and 11% ± 8% for dose of <42 Gy).[51] It occurs in as many as 65% of survivors of brain tumors, 43% of survivors of childhood nasopharyngeal tumors, 35% of bone marrow transplant recipients, and 10% to 15% of leukemia survivors.[52,53]

Mixed primary and central hypothyroidism can also occur and reflects separate injuries to the thyroid gland and the hypothalamus (e.g., radiation injury to both structures). TSH values may be elevated and, in addition, the secretory dynamics of TSH are abnormal, with a blunted or absent TSH surge or a delayed peak response to TSH-releasing hormone (TRH).[54] In a study of 208 childhood cancer survivors referred for evaluation of possible hypothyroidism or hypopituitarism, mixed hypothyroidism was present in 15 patients (7%).[54] Among patients who received TBI (fractionated total doses of 12–14.4 Gy) or craniospinal radiation (fractionated total cranial doses higher than 30 Gy), 15% had mixed hypothyroidism. In one study of 32 children treated for medulloblastoma, 56% developed hypothyroidism, including 38% with primary hypothyroidism and 19% with central hypothyroidism.[55]

Thyroid hormone replacement therapy using levothyroxine represents the mainstay of treatment of TSH deficiency. The dose of levothyroxine needs to be adjusted solely using plasma free T4 levels; the levels of TSH are expected to remain low during therapy, given the central nature of this deficiency.

Adrenal-corticotropin (ACTH) deficiency

ACTH deficiency is less common than other neuroendocrine deficits but should be suspected in patients who have a history of brain tumor (regardless of therapy modality), cranial radiation, GHD, or central hypothyroidism.[22,51,56-58] Although uncommon, ACTH deficiency can occur in patients treated with intracranial radiation doses of less than 24 Gy and has been reported to occur in fewer than 3% of patients after chemotherapy alone.[58] The diagnosis should be suspected when low plasma levels of morning cortisol are measured (a screening cortisol level collected at 8 a.m. that is 10 mcg/dl or more is reassuring for ACTH sufficiency, whereas a value of 5 mcg/dl or lower is suspicious for insufficiency). Confirmation is necessary using dynamic testing such as the low-dose ACTH stimulation test.[57] Because of the substantial risk of central adrenal insufficiency among survivors treated with cranial radiation doses exceeding 30 Gy to the hypothalamic-pituitary axis, endocrine monitoring with periodic dynamic testing as clinically indicated is recommended for this high-risk group.

Patients with partial ACTH deficiency may have only subtle symptoms unless they become ill. Illness can disrupt these patients’ usual homeostasis and cause a more severe, prolonged, or complicated course than expected. As in complete ACTH deficiency, incomplete or unrecognized ACTH deficiency can be life-threatening during concurrent illness.

The treatment of ACTH deficiency relies on replacement with hydrocortisone, including stress dosing in situations of illness to adjust to the body’s physiologically increased need for glucocorticoids.


Hyperprolactinemia has been described in patients who received radiation to the hypothalamus in doses higher than 50 Gy or who underwent surgery that disrupted the integrity of the pituitary stalk. Primary hypothyroidism may lead to hyperprolactinemia as a result of hyperplasia of thyrotrophs and lactotrophs, presumably due to TRH hypersecretion. The prolactin response to TRH is usually exaggerated in these patients.[22,59]

In general, hyperprolactinemia may result in delayed puberty, galactorrhea, menstrual irregularities, loss of libido, hot flashes, infertility, and osteopenia. However, hyperprolactinemia resulting from cranial radiation therapy is rarely symptomatic and, given its frequent associations with hypogonadism (both central and primary), rarely requires treatment.

Table 9. Pituitary Gland Late Effects
Predisposing TherapyEndocrine/Metabolic EffectsHealth Screening
BMI = body mass index; FSH = follicle-stimulating hormone; LH = luteinizing hormone; TSH = thyroid-stimulating hormone.
aTesticular volume measurements are not reliable in the assessment of pubertal development in boys exposed to chemotherapy or direct radiation to the testes.
bAppropriate only at diagnosis. TSH levels are not useful for follow-up during replacement therapy.
Radiation impacting hypothalamic-pituitary axisGrowth hormone deficiencyAssessment of nutritional status
Height, weight, BMI, Tanner stagea
Radiation impacting hypothalamic-pituitary axisPrecocious pubertyHeight, weight, BMI, Tanner stagea
FSH, LH, estradiol, or testosterone levels
Radiation impacting hypothalamic-pituitary axisGonadotropin deficiencyHistory: puberty, sexual function
Exam: Tanner stagea
FSH, LH, estradiol or testosterone levels
Radiation impacting hypothalamic-pituitary axisCentral adrenal insufficiencyHistory: failure to thrive, anorexia, episodic dehydration, hypoglycemia, lethargy, unexplained hypotension
Endocrine consultation for those with radiation dose ≥30 Gy
Radiation impacting hypothalamic-pituitary axisHyperprolactinemiaHistory/exam: galactorrhea
Prolactin level
Radiation impacting hypothalamic-pituitary axisOverweight/obesityHeight, weight, BMI
Blood pressure
Components of metabolic syndrome (abdominal obesity, hypertension, dyslipidemia, impaired glucose metabolism)Fasting blood glucose level and lipid profile
Radiation impacting hypothalamic-pituitary axisCentral hypothyroidismTSHb free thyroxine (free T4) level

Testis and Ovary

Testicular and ovarian hormonal functions are discussed in the Late Effects of the Reproductive System section of this summary.

Metabolic Syndrome

An increased risk of metabolic syndrome or its components has been observed among cancer survivors. Metabolic syndrome is highly associated with cardiovascular events and mortality. Definitions of metabolic syndrome are evolving but generally include a combination of central (abdominal) obesity with at least two or more of the following features:

  • Hypertension.
  • Atherogenic dyslipidemia (elevated triglycerides, reduced high-density lipoprotein [HDL] cholesterol).
  • Abnormal glucose metabolism (fasting hyperglycemia, hyperinsulinism, insulin resistance, diabetes mellitus type 2).[60]

Long-term survivors of ALL, especially those treated with cranial radiation, may have a higher prevalence of some potentially modifiable risk factors for cardiovascular disease such as impaired glucose tolerance or overt diabetes mellitus, dyslipidemia, hypertension, and obesity.[61-67] Results of selected studies are as follows:

  • In a study of 784 childhood long-term ALL survivors (median age, 31.7 years; median follow-up duration, 26.1 years), the prevalence of metabolic syndrome was 33.6%, which was significantly higher than that in a cohort of age-, sex-, and race-matched controls (N = 777) from the National Health and Nutrition Examination Survey (RR, 1.43; 95% CI, 1.22–1.69). Risk factors associated with metabolic syndrome in this study included older age and past exposures to cranial radiation therapy. Components of metabolic syndrome with significantly higher prevalence in ALL survivors than in controls included obesity, insulin resistance, hypertension, and decreased HDL levels.[66]
  • In a European cohort of 184 adult survivors of childhood leukemia (81.5% had ALL; median age, 21.2 years; median follow-up duration, 15.4 years), the prevalence of metabolic syndrome was 9.2%. In this study, exposure to TBI was found to be significantly associated with metabolic syndrome, with significant associations between TBI and hypertriglyceridemia, and low HDL and impaired fasting glucose.[67]

Abdominal radiation is an additional risk factor for metabolic syndrome as seen by the following:

  • Survivors of developmental or embryonal tumors treated with abdominal radiation are also at an increased risk of developing components of metabolic syndrome. In a prospective study of 164 long-term survivors (median follow-up time, 26 years), nephroblastoma (OR, 5.2) and neuroblastoma (OR, 6.5) survivors had more components of metabolic syndrome than did controls. Compared with nonirradiated survivors, survivors treated with abdominal radiation had higher blood pressure, triglycerides, low-density lipoprotein (LDL) cholesterol, and total fat percentage, which were assessed by dual-energy x-ray absorptiometry.[68]
  • Abdominal radiation therapy and TBI in the context of HSCT are increasingly recognized as independent risk factors for diabetes mellitus in childhood cancer survivors.[62,67-72]

A single-center cohort study of 532 adult (median age, 25.6 years) long-term (median follow-up time, 17.9 years) survivors observed that treatment but not genetic variation was strongly associated with the occurrence of the components of metabolic syndrome. Metabolic syndrome was more frequent in cranially (23.3%, P = .002) and abdominally (23.4%, P = .009) irradiated survivors than in nonirradiated survivors (10.0%).[71] In a cross-sectional study evaluating cardiovascular risk factors and insulin resistance in a clinically heterogeneous cohort of 319 childhood cancer survivors 5 or more years since diagnosis and 208 sibling controls, insulin resistance was significantly higher in survivors treated with cisplatin plus cranial irradiation (92% brain tumors) and in those who received steroids but no cisplatin (most leukemia survivors), compared with siblings.[73] Insulin resistance did not differ between survivors treated with surgery alone and siblings. Among survivors, analysis of individual chemotherapy agents failed to find associations with cardiovascular risk factors or insulin resistance. However, compared with siblings, nearly all chemotherapeutic agents, when examined individually, seemed to be associated with a high cardiovascular risk profile, characterized by lower total lean body mass, higher percentage fat mass, and insulin resistance.

Studies of glucose metabolism have observed the following:

  • In a European multicenter cohort of 2,520 childhood cancer survivors (median follow-up duration, 28 years), significant associations were found between diabetes mellitus and increasing doses of radiation therapy to the tail of the pancreas. These data support the contribution of radiation-induced islet cell injury to impairments of glucose homeostasis in this population.[72]
  • In a report from the CCSS that compared 8,599 childhood cancer survivors to 2,936 randomly selected sibling controls, and after adjustment for age, body mass index (BMI), and several demographic factors, the risk of diabetes mellitus was 1.8 times higher in survivors (95% CI, 1.3–2.5; P < .001). Significant associations were found between diabetes mellitus and young age at diagnosis (0–4 years), the use of alkylating agents and abdominal radiation or TBI. Also, survivors were significantly more likely to be receiving medication for hypertension, dyslipidemia, and/or diabetes mellitus than were sibling controls.[74]

The contribution of modifiable risk factors associated with metabolic syndrome to the risk of major cardiac events suggests that survivors are good candidates for targeted screening and lifestyle counseling regarding risk reduction measures.[75]

Table 10. Metabolic Syndrome Late Effects
Predisposing TherapyPotential Late EffectsHealth Screening
BMI = body mass index.
Total-body irradiationComponents of metabolic syndrome (abdominal obesity, hypertension, dyslipidemia, impaired glucose metabolism)Height, weight, BMI, blood pressure
Labs: fasting glucose and lipids

Obesity and Being Overweight

To date, the primary cancer groups recognized with an increased incidence of treatment-related obesity are ALL [76-85] and CNS tumor [16,17] survivors treated with cranial radiation therapy.[86,87] In addition, craniopharyngioma survivors have a substantially increased risk of extreme obesity because of the tumor location and the hypothalamic damage resulting from surgical resection.[88-93]

In addition to treatment factors, lifestyle factors and medication use can also contribute to the risk of obesity. CCSS investigators reported the following independent risk factors for obesity in childhood cancer survivors:[94]

  • Cancer diagnosed at ages 5 to 9 years (RR, 1.12; 95% CI, 1.01–1.24).
  • Abnormal physical functioning (RR, 1.19; 95% CI, 1.06–1.33).
  • Hypothalamic/pituitary radiation dose of 20 Gy to 30 Gy (RR, 1.17; 95% CI, 1.05–1.3; P = .01).
  • Specific antidepressant use (paroxetine) (RR, 1.29; 95% CI, 1.08–1.54).

Survivors who adhered to the U.S. Centers for Disease Control and Prevention guidelines for vigorous physical activity (RR, 0.90; 95% CI, 0.82–0.97; P = .01) and who had a medium amount of anxiety (RR, 0.86; 95% CI, 0.75–0.99; P = .04) had a lower risk of obesity.[94]

The development of obesity after cranial radiation therapy is multifactorial and includes the following:[82,95,96]

  • GHD.
  • Leptin sensitivity.
  • Reduced levels of physical activity and energy expenditure.

Body composition alterations after childhood ALL

Moderate-dose cranial radiation therapy (18–24 Gy) among ALL survivors is associated with obesity, particularly in females treated at a young age.[63,79,82,97] Female adult survivors of childhood ALL who were treated with cranial radiation therapy of 24 Gy before age 5 years are four times more likely to be obese than are women who have not been treated for a cancer.[79] In addition, women treated with 18 Gy to 24 Gy cranial radiation therapy before age 10 years have a substantially greater rate of increase in their BMI through their young adult years than do women who were treated for ALL with only chemotherapy or women in the general population.[82] It appears that these women also have a significantly increased visceral adiposity and associated insulin resistance.[98,99] These outcomes are attenuated in males.

ALL therapy regimens are associated with increases in BMI shortly after completion of therapy, and possibly with a higher risk of obesity in the long term.[83-85,100,101] Survivors of childhood ALL treated with chemotherapy alone also exhibit long-term changes in body composition, with relative increases in body fat [99,102-104] and visceral adiposity in comparison to lean mass.[98] These changes cannot be detected if BMI alone is used in the assessment of metabolic risk in this population. In a report from the CCSS, adult survivors of childhood ALL treated with chemotherapy alone did not have significantly higher rates of obesity than did sibling controls,[79] nor were there differences in BMI changes between these groups after a subsequent period of follow-up that averaged 7.8 years.[82] It is important to note, however, that results from the CCSS were based on self-reported height and weight measurements.

Body composition alterations after treatment for CNS tumors

Among brain tumor survivors treated with higher doses of cranial radiation therapy, only females treated at a younger age appear to be at increased risk for obesity.[105]

Body composition alterations after hematopoietic cell transplantation

Survivors of childhood cancer treated with TBI in preparation for an allogeneic HSCT have increased measures of body fatness (percent fat) while often having a normal BMI.[69,106] Longitudinal decline in BMI related to substantial decrease in lean mass has been observed among survivors of hematological malignancies treated with allogeneic HSCT. This finding was largely attributable to TBI conditioning and severity of chronic GVHD.[107]

Body composition and frailty

Young adult childhood cancer survivors have a higher-than-expected prevalence of frailty, a phenotype characterized by low muscle mass, self-reported exhaustion, low energy expenditure, slow walking speed, and weakness. The frailty phenotype increases in prevalence with aging, and has been associated with excess risk of mortality and onset of chronic conditions. Ongoing research aims to elucidate the pathophysiology of frailty and develop/test interventions to prevent or reverse this condition.[108]

Table 11. Body Composition Late Effects
Predisposing TherapyPotential Late EffectsHealth Screening
BMI = body mass index.
Cranial radiation therapyOverweight/obesityHeight, weight, BMI, blood pressure
Labs: fasting glucose and lipids

Refer to the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers for endocrine and metabolic syndrome late effects information, including risk factors, evaluation, and health counseling.


  1. Gleeson HK, Darzy K, Shalet SM: Late endocrine, metabolic and skeletal sequelae following treatment of childhood cancer. Best Pract Res Clin Endocrinol Metab 16 (2): 335-48, 2002. [PUBMED Abstract]
  2. Hudson MM, Ness KK, Gurney JG, et al.: Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 309 (22): 2371-81, 2013. [PUBMED Abstract]
  3. Bölling T, Geisenheiser A, Pape H, et al.: Hypothyroidism after head-and-neck radiotherapy in children and adolescents: preliminary results of the "Registry for the Evaluation of Side Effects After Radiotherapy in Childhood and Adolescence" (RiSK). Int J Radiat Oncol Biol Phys 81 (5): e787-91, 2011. [PUBMED Abstract]
  4. Sklar C, Whitton J, Mertens A, et al.: Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 85 (9): 3227-32, 2000. [PUBMED Abstract]
  5. Bhatti P, Veiga LH, Ronckers CM, et al.: Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res 174 (6): 741-52, 2010. [PUBMED Abstract]
  6. Haddy N, El-Fayech C, Guibout C, et al.: Thyroid adenomas after solid cancer in childhood. Int J Radiat Oncol Biol Phys 84 (2): e209-15, 2012. [PUBMED Abstract]
  7. Ronckers CM, Sigurdson AJ, Stovall M, et al.: Thyroid cancer in childhood cancer survivors: a detailed evaluation of radiation dose response and its modifiers. Radiat Res 166 (4): 618-28, 2006. [PUBMED Abstract]
  8. Sigurdson AJ, Ronckers CM, Mertens AC, et al.: Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 365 (9476): 2014-23, 2005 Jun 11-17. [PUBMED Abstract]
  9. van Santen HM, Tytgat GA, van de Wetering MD, et al.: Differentiated thyroid carcinoma after 131I-MIBG treatment for neuroblastoma during childhood: description of the first two cases. Thyroid 22 (6): 643-6, 2012. [PUBMED Abstract]
  10. Veiga LH, Lubin JH, Anderson H, et al.: A pooled analysis of thyroid cancer incidence following radiotherapy for childhood cancer. Radiat Res 178 (4): 365-76, 2012. [PUBMED Abstract]
  11. Kovalchik SA, Ronckers CM, Veiga LH, et al.: Absolute risk prediction of second primary thyroid cancer among 5-year survivors of childhood cancer. J Clin Oncol 31 (1): 119-27, 2013. [PUBMED Abstract]
  12. Brignardello E, Corrias A, Isolato G, et al.: Ultrasound screening for thyroid carcinoma in childhood cancer survivors: a case series. J Clin Endocrinol Metab 93 (12): 4840-3, 2008. [PUBMED Abstract]
  13. Vivanco M, Dalle JH, Alberti C, et al.: Malignant and benign thyroid nodules after total body irradiation preceding hematopoietic cell transplantation during childhood. Eur J Endocrinol 167 (2): 225-33, 2012. [PUBMED Abstract]
  14. Metzger ML, Howard SC, Hudson MM, et al.: Natural history of thyroid nodules in survivors of pediatric Hodgkin lymphoma. Pediatr Blood Cancer 46 (3): 314-9, 2006. [PUBMED Abstract]
  15. Sanders JE, Hoffmeister PA, Woolfrey AE, et al.: Thyroid function following hematopoietic cell transplantation in children: 30 years' experience. Blood 113 (2): 306-8, 2009. [PUBMED Abstract]
  16. Gurney JG, Kadan-Lottick NS, Packer RJ, et al.: Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 97 (3): 663-73, 2003. [PUBMED Abstract]
  17. Constine LS, Woolf PD, Cann D, et al.: Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 328 (2): 87-94, 1993. [PUBMED Abstract]
  18. Sklar CA: Growth and neuroendocrine dysfunction following therapy for childhood cancer. Pediatr Clin North Am 44 (2): 489-503, 1997. [PUBMED Abstract]
  19. Ramelli GP, von der Weid N, Stanga Z, et al.: Suprasellar germinomas in childhood and adolescence: diagnostic pitfalls. J Pediatr Endocrinol Metab 11 (6): 693-7, 1998 Nov-Dec. [PUBMED Abstract]
  20. Vinchon M, Baroncini M, Leblond P, et al.: Morbidity and tumor-related mortality among adult survivors of pediatric brain tumors: a review. Childs Nerv Syst 27 (5): 697-704, 2011. [PUBMED Abstract]
  21. Fahrner B, Prosch H, Minkov M, et al.: Long-term outcome of hypothalamic pituitary tumors in Langerhans cell histiocytosis. Pediatr Blood Cancer 58 (4): 606-10, 2012. [PUBMED Abstract]
  22. Darzy KH, Shalet SM: Hypopituitarism following radiotherapy. Pituitary 12 (1): 40-50, 2009. [PUBMED Abstract]
  23. Mulder RL, Kremer LC, van Santen HM, et al.: Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review. Cancer Treat Rev 35 (7): 616-32, 2009. [PUBMED Abstract]
  24. Merchant TE, Goloubeva O, Pritchard DL, et al.: Radiation dose-volume effects on growth hormone secretion. Int J Radiat Oncol Biol Phys 52 (5): 1264-70, 2002. [PUBMED Abstract]
  25. Merchant TE, Rose SR, Bosley C, et al.: Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol 29 (36): 4776-80, 2011. [PUBMED Abstract]
  26. Sklar C, Mertens A, Walter A, et al.: Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1800 and 2400 centigrays of cranial irradiation. J Pediatr 123 (1): 59-64, 1993. [PUBMED Abstract]
  27. Schriock EA, Schell MJ, Carter M, et al.: Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. J Clin Oncol 9 (3): 400-5, 1991. [PUBMED Abstract]
  28. Chow EJ, Friedman DL, Yasui Y, et al.: Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Pediatr 150 (4): 370-5, 375.e1, 2007. [PUBMED Abstract]
  29. Vandecruys E, Dhooge C, Craen M, et al.: Longitudinal linear growth and final height is impaired in childhood acute lymphoblastic leukemia survivors after treatment without cranial irradiation. J Pediatr 163 (1): 268-73, 2013. [PUBMED Abstract]
  30. Ogilvy-Stuart AL, Clark DJ, Wallace WH, et al.: Endocrine deficit after fractionated total body irradiation. Arch Dis Child 67 (9): 1107-10, 1992. [PUBMED Abstract]
  31. Willi SM, Cooke K, Goldwein J, et al.: Growth in children after bone marrow transplantation for advanced neuroblastoma compared with growth after transplantation for leukemia or aplastic anemia. J Pediatr 120 (5): 726-32, 1992. [PUBMED Abstract]
  32. Wingard JR, Plotnick LP, Freemer CS, et al.: Growth in children after bone marrow transplantation: busulfan plus cyclophosphamide versus cyclophosphamide plus total body irradiation. Blood 79 (4): 1068-73, 1992. [PUBMED Abstract]
  33. Bernard F, Bordigoni P, Simeoni MC, et al.: Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI. Bone Marrow Transplant 43 (8): 637-42, 2009. [PUBMED Abstract]
  34. Chemaitilly W, Sklar CA: Endocrine complications of hematopoietic stem cell transplantation. Endocrinol Metab Clin North Am 36 (4): 983-98; ix, 2007. [PUBMED Abstract]
  35. Huma Z, Boulad F, Black P, et al.: Growth in children after bone marrow transplantation for acute leukemia. Blood 86 (2): 819-24, 1995. [PUBMED Abstract]
  36. Socié G, Salooja N, Cohen A, et al.: Nonmalignant late effects after allogeneic stem cell transplantation. Blood 101 (9): 3373-85, 2003. [PUBMED Abstract]
  37. Cohen A, Rovelli A, Bakker B, et al.: Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. Blood 93 (12): 4109-15, 1999. [PUBMED Abstract]
  38. Chemaitilly W, Robison LL: Safety of growth hormone treatment in patients previously treated for cancer. Endocrinol Metab Clin North Am 41 (4): 785-92, 2012. [PUBMED Abstract]
  39. Sklar CA, Mertens AC, Mitby P, et al.: Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 87 (7): 3136-41, 2002. [PUBMED Abstract]
  40. Ergun-Longmire B, Mertens AC, Mitby P, et al.: Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 91 (9): 3494-8, 2006. [PUBMED Abstract]
  41. Bogarin R, Steinbok P: Growth hormone treatment and risk of recurrence or progression of brain tumors in children: a review. Childs Nerv Syst 25 (3): 273-9, 2009. [PUBMED Abstract]
  42. Patterson BC, Chen Y, Sklar CA, et al.: Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. J Clin Endocrinol Metab 99 (6): 2030-7, 2014. [PUBMED Abstract]
  43. Nandagopal R, Laverdière C, Mulrooney D, et al.: Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. Horm Res 69 (2): 65-74, 2008. [PUBMED Abstract]
  44. Chemaitilly W, Sklar CA: Endocrine complications in long-term survivors of childhood cancers. Endocr Relat Cancer 17 (3): R141-59, 2010. [PUBMED Abstract]
  45. Didcock E, Davies HA, Didi M, et al.: Pubertal growth in young adult survivors of childhood leukemia. J Clin Oncol 13 (10): 2503-7, 1995. [PUBMED Abstract]
  46. Shalet SM, Crowne EC, Didi MA, et al.: Irradiation-induced growth failure. Baillieres Clin Endocrinol Metab 6 (3): 513-26, 1992. [PUBMED Abstract]
  47. Greulich WW, Pyle SI: Radiographic Atlas of Skeletal Development of Hand and Wrist. 2nd ed. Stanford, Ca: Stanford University Press, 1959.
  48. Gleeson HK, Stoeter R, Ogilvy-Stuart AL, et al.: Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement. J Clin Endocrinol Metab 88 (8): 3682-9, 2003. [PUBMED Abstract]
  49. Chow EJ, Friedman DL, Yasui Y, et al.: Timing of menarche among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 50 (4): 854-8, 2008. [PUBMED Abstract]
  50. Armstrong GT, Whitton JA, Gajjar A, et al.: Abnormal timing of menarche in survivors of central nervous system tumors: A report from the Childhood Cancer Survivor Study. Cancer 115 (11): 2562-70, 2009. [PUBMED Abstract]
  51. Laughton SJ, Merchant TE, Sklar CA, et al.: Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J Clin Oncol 26 (7): 1112-8, 2008. [PUBMED Abstract]
  52. Rose SR: Cranial irradiation and central hypothyroidism. Trends Endocrinol Metab 12 (3): 97-104, 2001. [PUBMED Abstract]
  53. Cheuk DK, Billups CA, Martin MG, et al.: Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer 117 (1): 197-206, 2011. [PUBMED Abstract]
  54. Rose SR, Lustig RH, Pitukcheewanont P, et al.: Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab 84 (12): 4472-9, 1999. [PUBMED Abstract]
  55. Paulino AC: Hypothyroidism in children with medulloblastoma: a comparison of 3600 and 2340 cGy craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 53 (3): 543-7, 2002. [PUBMED Abstract]
  56. Patterson BC, Truxillo L, Wasilewski-Masker K, et al.: Adrenal function testing in pediatric cancer survivors. Pediatr Blood Cancer 53 (7): 1302-7, 2009. [PUBMED Abstract]
  57. Kazlauskaite R, Evans AT, Villabona CV, et al.: Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab 93 (11): 4245-53, 2008. [PUBMED Abstract]
  58. Rose SR, Danish RK, Kearney NS, et al.: ACTH deficiency in childhood cancer survivors. Pediatr Blood Cancer 45 (6): 808-13, 2005. [PUBMED Abstract]
  59. Constine LS, Rubin P, Woolf PD, et al.: Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies. J Clin Oncol 5 (11): 1841-51, 1987. [PUBMED Abstract]
  60. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (25): 3143-421, 2002. [PUBMED Abstract]
  61. Chow EJ, Simmons JH, Roth CL, et al.: Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation. Biol Blood Marrow Transplant 16 (12): 1674-81, 2010. [PUBMED Abstract]
  62. Surapolchai P, Hongeng S, Mahachoklertwattana P, et al.: Impaired glucose tolerance and insulin resistance in survivors of childhood acute lymphoblastic leukemia: prevalence and risk factors. J Pediatr Hematol Oncol 32 (5): 383-9, 2010. [PUBMED Abstract]
  63. Veringa SJ, van Dulmen-den Broeder E, Kaspers GJ, et al.: Blood pressure and body composition in long-term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 58 (2): 278-82, 2012. [PUBMED Abstract]
  64. Steinberger J, Sinaiko AR, Kelly AS, et al.: Cardiovascular risk and insulin resistance in childhood cancer survivors. J Pediatr 160 (3): 494-9, 2012. [PUBMED Abstract]
  65. Gurney JG, Ness KK, Sibley SD, et al.: Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer 107 (6): 1303-12, 2006. [PUBMED Abstract]
  66. Nottage KA, Ness KK, Li C, et al.: Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia - From the St. Jude Lifetime Cohort. Br J Haematol 165 (3): 364-74, 2014. [PUBMED Abstract]
  67. Oudin C, Simeoni MC, Sirvent N, et al.: Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood 117 (17): 4442-8, 2011. [PUBMED Abstract]
  68. van Waas M, Neggers SJ, Raat H, et al.: Abdominal radiotherapy: a major determinant of metabolic syndrome in nephroblastoma and neuroblastoma survivors. PLoS One 7 (12): e52237, 2012. [PUBMED Abstract]
  69. Neville KA, Cohn RJ, Steinbeck KS, et al.: Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: prevalence and risk factors. J Clin Endocrinol Metab 91 (11): 4401-7, 2006. [PUBMED Abstract]
  70. Baker KS, Ness KK, Steinberger J, et al.: Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 109 (4): 1765-72, 2007. [PUBMED Abstract]
  71. van Waas M, Neggers SJ, Uitterlinden AG, et al.: Treatment factors rather than genetic variation determine metabolic syndrome in childhood cancer survivors. Eur J Cancer 49 (3): 668-75, 2013. [PUBMED Abstract]
  72. de Vathaire F, El-Fayech C, Ben Ayed FF, et al.: Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors: a retrospective cohort study. Lancet Oncol 13 (10): 1002-10, 2012. [PUBMED Abstract]
  73. Baker KS, Chow EJ, Goodman PJ, et al.: Impact of treatment exposures on cardiovascular risk and insulin resistance in childhood cancer survivors. Cancer Epidemiol Biomarkers Prev 22 (11): 1954-63, 2013. [PUBMED Abstract]
  74. Meacham LR, Chow EJ, Ness KK, et al.: Cardiovascular risk factors in adult survivors of pediatric cancer--a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 19 (1): 170-81, 2010. [PUBMED Abstract]
  75. Armstrong GT, Oeffinger KC, Chen Y, et al.: Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 31 (29): 3673-80, 2013. [PUBMED Abstract]
  76. Craig F, Leiper AD, Stanhope R, et al.: Sexually dimorphic and radiation dose dependent effect of cranial irradiation on body mass index. Arch Dis Child 81 (6): 500-4, 1999. [PUBMED Abstract]
  77. Mayer EI, Reuter M, Dopfer RE, et al.: Energy expenditure, energy intake and prevalence of obesity after therapy for acute lymphoblastic leukemia during childhood. Horm Res 53 (4): 193-9, 2000. [PUBMED Abstract]
  78. Nysom K, Holm K, Michaelsen KF, et al.: Degree of fatness after treatment for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab 84 (12): 4591-6, 1999. [PUBMED Abstract]
  79. Oeffinger KC, Mertens AC, Sklar CA, et al.: Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 21 (7): 1359-65, 2003. [PUBMED Abstract]
  80. Sklar CA, Mertens AC, Walter A, et al.: Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol 35 (2): 91-5, 2000. [PUBMED Abstract]
  81. Van Dongen-Melman JE, Hokken-Koelega AC, Hählen K, et al.: Obesity after successful treatment of acute lymphoblastic leukemia in childhood. Pediatr Res 38 (1): 86-90, 1995. [PUBMED Abstract]
  82. Garmey EG, Liu Q, Sklar CA, et al.: Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 26 (28): 4639-45, 2008. [PUBMED Abstract]
  83. Chow EJ, Pihoker C, Hunt K, et al.: Obesity and hypertension among children after treatment for acute lymphoblastic leukemia. Cancer 110 (10): 2313-20, 2007. [PUBMED Abstract]
  84. Withycombe JS, Post-White JE, Meza JL, et al.: Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961. Pediatr Blood Cancer 53 (7): 1249-54, 2009. [PUBMED Abstract]
  85. Dalton VK, Rue M, Silverman LB, et al.: Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol 21 (15): 2953-60, 2003. [PUBMED Abstract]
  86. Meacham LR, Gurney JG, Mertens AC, et al.: Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood Cancer Survivor Study. Cancer 103 (8): 1730-9, 2005. [PUBMED Abstract]
  87. Nathan PC, Jovcevska V, Ness KK, et al.: The prevalence of overweight and obesity in pediatric survivors of cancer. J Pediatr 149 (4): 518-25, 2006. [PUBMED Abstract]
  88. Sahakitrungruang T, Klomchan T, Supornsilchai V, et al.: Obesity, metabolic syndrome, and insulin dynamics in children after craniopharyngioma surgery. Eur J Pediatr 170 (6): 763-9, 2011. [PUBMED Abstract]
  89. Müller HL: Childhood craniopharyngioma--current concepts in diagnosis, therapy and follow-up. Nat Rev Endocrinol 6 (11): 609-18, 2010. [PUBMED Abstract]
  90. Müller HL: Childhood craniopharyngioma: current controversies on management in diagnostics, treatment and follow-up. Expert Rev Neurother 10 (4): 515-24, 2010. [PUBMED Abstract]
  91. Simoneau-Roy J, O'Gorman C, Pencharz P, et al.: Insulin sensitivity and secretion in children and adolescents with hypothalamic obesity following treatment for craniopharyngioma. Clin Endocrinol (Oxf) 72 (3): 364-70, 2010. [PUBMED Abstract]
  92. May JA, Krieger MD, Bowen I, et al.: Craniopharyngioma in childhood. Adv Pediatr 53: 183-209, 2006. [PUBMED Abstract]
  93. Müller HL, Gebhardt U, Teske C, et al.: Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. Eur J Endocrinol 165 (1): 17-24, 2011. [PUBMED Abstract]
  94. Green DM, Cox CL, Zhu L, et al.: Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 30 (3): 246-55, 2012. [PUBMED Abstract]
  95. Oeffinger KC: Are survivors of acute lymphoblastic leukemia (ALL) at increased risk of cardiovascular disease? Pediatr Blood Cancer 50 (2 Suppl): 462-7; discussion 468, 2008. [PUBMED Abstract]
  96. Brennan BM, Rahim A, Blum WF, et al.: Hyperleptinaemia in young adults following cranial irradiation in childhood: growth hormone deficiency or leptin insensitivity? Clin Endocrinol (Oxf) 50 (2): 163-9, 1999. [PUBMED Abstract]
  97. Didi M, Didcock E, Davies HA, et al.: High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood. J Pediatr 127 (1): 63-7, 1995. [PUBMED Abstract]
  98. Janiszewski PM, Oeffinger KC, Church TS, et al.: Abdominal obesity, liver fat, and muscle composition in survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab 92 (10): 3816-21, 2007. [PUBMED Abstract]
  99. Oeffinger KC, Adams-Huet B, Victor RG, et al.: Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 27 (22): 3698-704, 2009. [PUBMED Abstract]
  100. Kohler JA, Moon RJ, Wright S, et al.: Increased adiposity and altered adipocyte function in female survivors of childhood acute lymphoblastic leukaemia treated without cranial radiation. Horm Res Paediatr 75 (6): 433-40, 2011. [PUBMED Abstract]
  101. Zhang FF, Rodday AM, Kelly MJ, et al.: Predictors of being overweight or obese in survivors of pediatric acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer 61 (7): 1263-9, 2014. [PUBMED Abstract]
  102. Warner JT, Evans WD, Webb DK, et al.: Body composition of long-term survivors of acute lymphoblastic leukaemia. Med Pediatr Oncol 38 (3): 165-72, 2002. [PUBMED Abstract]
  103. Miller TL, Lipsitz SR, Lopez-Mitnik G, et al.: Characteristics and determinants of adiposity in pediatric cancer survivors. Cancer Epidemiol Biomarkers Prev 19 (8): 2013-22, 2010. [PUBMED Abstract]
  104. Jarfelt M, Lannering B, Bosaeus I, et al.: Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol 153 (1): 81-9, 2005. [PUBMED Abstract]
  105. Gurney JG, Ness KK, Stovall M, et al.: Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study. J Clin Endocrinol Metab 88 (10): 4731-9, 2003. [PUBMED Abstract]
  106. Nysom K, Holm K, Michaelsen KF, et al.: Degree of fatness after allogeneic BMT for childhood leukaemia or lymphoma. Bone Marrow Transplant 27 (8): 817-20, 2001. [PUBMED Abstract]
  107. Inaba H, Yang J, Kaste SC, et al.: Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol 30 (32): 3991-7, 2012. [PUBMED Abstract]
  108. Ness KK, Krull KR, Jones KE, et al.: Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study. J Clin Oncol 31 (36): 4496-503, 2013. [PUBMED Abstract]
  • Updated: December 17, 2014